[{"orgOrder":0,"company":"ViroCell Biologics","sponsor":"AvenCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"AVC-203","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Preclinical","graph3":"ViroCell Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViroCell Biologics \/ AvenCell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"ViroCell Biologics \/ AvenCell Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by ViroCell Biologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : The collaboration with ViroCell will help manufacture CAR-T cell therapy products, including AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B-cell malignancies.

                          Product Name : AVC-203

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 29, 2025

                          Lead Product(s) : AVC-203

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : AvenCell Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank